Scholars Central

Conference abstractPublished 27 Oct 2014

Being-similar: From benchside to bedside

Authors: Manish Mahajan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biosimilars has been the topic of contention, enthusiasm and research for the past couple decades both to the industry and regulatory authorities. With the introduction of latest technology at ?omics front, one could expect further deliberations in not only easy lead identification and therapeutic targets but also growing interest in biopharmaceutical companies to harness this opportunity in discovering the bio-betters or similars. Although we still debate upon the regulatory challenges of whether the innovator product and its similar is replaceable or not, there lies a bigger uncertainty at the place of its advocator i.e., the physician. Various surveys have demonstrated that physician have little clue about biosimilars and still apprehensive about its quality and safety. This behavior is not in sync with the current policy of low income countries where public health is not only a state affair but also with a limited budget. The onus is not only on the industry but also on the other stake holders to justify the very purpose of ?Being?Similar?.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Manish Mahajan”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels